Grace Therapeutics (GRCE) Stock Forecast: StockMap's 2-Week Call

GRCE stock forecast: StockMap's model makes no two-week call on Grace Therapeutics after the Nov 19 close: its evidence is split, 6 reasons for and 9 against. Right in 3 of 6 two-week windows on GRCE since Aug 21; by chance, a call on the same dates was right 58% of the time.

Grace Therapeutics last closed at $1.73, +0.00% on the session.

Against the IVW growth benchmark the position is +2.33% over the forecast window.

Grace Therapeutics' market cap is $36.39M as of November 19, 2026.

No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -13 (too close to call).

Where GRCE sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 6 bullish and 9 bearish.

Agreement across those insights is 60%.

38 daily calls for GRCE so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Grace Therapeutics in the 22nd percentile on return on equity, where 100 is best.

Grace Therapeutics is classified under Health Care / Pharmaceuticals.

StockMap tracks Grace Therapeutics as the 113th largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.

On that composite Grace Therapeutics ranks 29th of 153 in the group, against a group median of -0.36.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Grace Therapeutics (GRCE) — StockMap 2-week forecast & tracked accuracy